Novo Nordisk says the US FDA has approved a once daily pill version of Wegovy, described as the first approved pill of its kind The company said trials showed average weight loss of 16.6%, with about a third of roughly 1,300 participants losing 20% or more Novo Nordisk expects a US launch in early January 2026, with investors pushing shares up sharply after the announcement amid strong competition in the weight loss market US regulators have approved an oral version of Wegovy for chronic weight management, giving Novo Nordisk the first daily pill in this drug class cleared for obesity treatment, according to the company and US media reports
Mounjaro (tirzepatide) hasnt been thoroughly tested on pregnant individuals, resulting in a significant safety gap
It's 'Why is my oxidative stress so high that I need continuous supplementation to feel normal?' Glutathione is a patch, not a fix
As the science advances and follow-up studies expand, patients and providers will have increasingly powerful tools to achieve health goals that were once elusive
These changes in enzyme activity may directly impact lipid metabolic pathways (Fig
You can cancel anytime through the patient portal in two clicks